PHAR­MA­CEU­TI­CALS

Modern Healthcare - - NEWS MAKERS -

J. Michael Pear­son, CEO of Valeant Phar­ma­ceu­ti­cals, will be tak­ing a med­i­cal leave of ab­sence af­ter be­ing hos­pi­tal­ized with a se­vere case of pneu­mo­nia. Pear­son, 56, be­gan his ca­reer with Valeant in 2008, af­ter serv­ing as head of global phar­ma­ceu­ti­cal prac­tices for 23 years with con­sult­ing firm McKin­sey & Co. Valeant re­leased no fur­ther de­tails about Pear­son’s leave of ab­sence, but an­nounced three ex­ec­u­tives who will take over for him in the in­terim.

Robert Chai-Onn, 44, is the com­pany’s gen­eral coun­sel and over­sees cor­po­rate le­gal teams and ac­tiv­i­ties. Chai-Onn joined Valeant in 2004.

Dr. Ari Kellen, 51, serves as Valeant’s ex­ec­u­tive VP and com­pany group chair­man. Kellen is re­spon­si­ble for U.S. der­ma­tol­ogy, Bausch and Lomb and Valeant’s Latin Amer­i­can busi­ness. He joined the com­pany in Jan­uary 2014.

Robert Rosiello, 57, is the com­pany’s ex­ec­u­tive VP and CFO. Be­fore his ap­point­ment as CFO in July, he spent 30 years at McKin­sey & Co., where he as­sisted health­care com­pa­nies with merg­ers and ac­qui­si­tions.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.